# Nob Hill Therapeutics

> Nob Hill Therapeutics is an Albuquerque, New Mexico respiratory healthcare company re-envisioning inhalation medicines. Its patented DryNeb dry powder nebulizer is designed to deliver high doses of medicine directly to the lungs while a patient breathes normally, combining the strengths of dry powder inhalers and liquid nebulizers. Spun out of VIC Technology Venture Development and based on the Lovelace Respiratory Research Institute campus, the company is targeting hard-to-treat lung diseases such as lower respiratory tract infections, lung fungal infections and lung cancer.

- **Founded:** 2019
- **Headquarters:** Albuquerque, New Mexico, United States
- **Founders:** Noel Greenberger (CEO), Paul Atkins (Executive Chairman), Dr. Davies-Cutting (Technical Leadership)
- **Team size:** ~7 employees
- **Products:** DryNeb (Dry Powder Nebulizer)
- **Notable:** Developed the world's first and only dry powder nebulizer (DryNeb) inhalation platform, Raised a $3M Series A in August 2024 led by Tramway Venture Partners, Awarded multiple HHS Phase II grants, including a lung cancer therapy grant (2023)

## Products & services

- **DryNeb (Dry Powder Nebulizer)** — A patented inhalation drug delivery platform that combines the best attributes of dry powder inhalers and liquid nebulizers. It delivers reproducible, high doses of medicine directly to the lungs while a patient breathes normally - no special inhalation maneuver, breath-hold or coordination required - and is designed to work across all ages and lung capacities, including patients with compromised lung function.

## Achievements

- Developed the world's first and only dry powder nebulizer (DryNeb) inhalation platform
- Raised a $3M Series A in August 2024 led by Tramway Venture Partners
- Awarded multiple HHS Phase II grants, including a lung cancer therapy grant (2023)
- Selected as a finalist for the RESI Innovator's Pitch Challenge (2021)
- Featured poster presentation at the Respiratory Innovation Summit (2023)
- Expanded its Strategic Advisory Board with respiratory drug development and pulmonary medicine leaders (2025)

## Latest updates

- **2025-06** — Expanded Strategic Advisory Board with two leaders in respiratory drug development and pulmonary medicine.
- **2024-08** — Closed $3M Series A led by Tramway Venture Partners with TCA Venture Group and VIC; Chris Japp joined the board.
- **2023-10** — Awarded an HHS Phase II grant for a lung cancer therapy program.

## Links

- Website: https://nobhilltherapeutics.com
- LinkedIn: https://www.linkedin.com/company/nob-hill-therapeutics

---

Profile page: https://yespress.io/nob-hill-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-08